THE DIFFERENTIAL BEHAVIORAL-EFFECTS OF BENZAZEPINE D-1 DOPAMINE AGONISTS WITH VARYING EFFICACIES, CO-ADMINISTERED WITH QUINPIROLE IN PRIMATE AND RODENT MODELS OF PARKINSONS-DISEASE

被引:35
|
作者
GNANALINGHAM, KK
HUNTER, AJ
JENNER, P
MARSDEN, CD
机构
[1] UNIV LONDON KINGS COLL,DIV BIOMED SCI,PARKINSONS DIS SOC EXPTL RES LABS,LONDON WC2R 2LS,ENGLAND
[2] SMITHKLINE BEECHAM PHARMACEUT,HARLOW CM19 5AD,ESSEX,ENGLAND
[3] UNIV LONDON,NATL HOSP NEUROL,DEPT CLIN NEUROL,LONDON,ENGLAND
关键词
D-1 DOPAMINE AGONISTS; QUINPIROLE; MPTP; MARMOSET; RAT; 6-HYDROXYDOPAMINE; BEHAVIOR;
D O I
10.1007/BF02246103
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The effects of co-administration of quinpirole with benzazepine D-1 dopamine (DA) agonists possessing full/supramaximal (SKF 80723 and SKF 82958), partial (SKF 38393 and SKF 75670) and no efficacies (SKF 83959) in stimulating adenylate cyclase (AC) were investigated in rodent and primate models of Parkinson's disease (PD). In rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, co-administration of SKF 38393 (7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine), SKF 75670 (3-CH3 analogue), SKF 80723 (6-Br analogue), SKF 83959 (6-Cl, 3-CH3, 3'-CH3 analogue) and SKF 82958 (6-Cl, 3-C3H5 analogue) strongly potentiated the contralateral circling induced by quinpirole. In MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treated common marmosets, administration of quinpirole alone increased locomotor activity and reversed motor deficits. Grooming and oral activity were unaltered. Go-administration of SKF 38393 and SKF 75670 inhibited the quinpirole-induced changes in locomotor activity and motor disability. The combined treatment of SKF 80723 or SKF 82958 with quinpirole had no overall effect on locomotor activity or motor disability. In contrast, SKF 83959 extended the duration of the quinpirole-induced increase in locomotor activity with corresponding decreases in motor disability. Go-administration of high doses of SKF 82958 and more especially SKF 83959 and SKF 80723, with quinpirole induced hyperexcitability and seizures. Oral activity and grooming were unaltered following the co-administration of benzazepine derivatives with quinpirole. The ability of some benzazepine D-1 DA agonists to prolong the antiparkinsonian effects of quinpirole in the MPTP-treated marmoset may indicate a role for certain D-1 DA agonists in the clinical treatment of PD. In general, the behavioural responses to the combined administration of benzazepines with quinpirole in the 6-OHDA lesioned rat and more especially the MPTP-treated marmoset failed to correlate with their ability to stimulate AC. These observations further implicate a behavioural role for D-1 DA receptors not linked to AC.
引用
收藏
页码:287 / 297
页数:11
相关论文
共 14 条
  • [1] SELECTIVE DOPAMINE ANTAGONIST PRETREATMENT ON THE ANTIPARKINSONIAN EFFECTS OF BENZAZEPINE D-1 DOPAMINE AGONISTS IN RODENT AND PRIMATE MODELS OF PARKINSONS-DISEASE - THE DIFFERENTIAL-EFFECTS OF D-1 DOPAMINE ANTAGONISTS IN THE PRIMATE
    GNANALINGHAM, KK
    HUNTER, AJ
    JENNER, P
    MARSDEN, CD
    PSYCHOPHARMACOLOGY, 1995, 117 (04) : 403 - 412
  • [2] DIFFERENTIAL ANTI-PARKINSONIAN EFFECTS OF BENZAZEPINE D-1 DOPAMINE AGONISTS WITH VARYING EFFICACIES IN THE MPTP-TREATED COMMON MARMOSET
    GNANALINGHAM, KK
    EROL, DD
    HUNTER, AJ
    SMITH, LA
    JENNER, P
    MARSDEN, CD
    PSYCHOPHARMACOLOGY, 1995, 117 (03) : 275 - 286
  • [3] A-86929 - A SELECTIVE DOPAMINE D1 RECEPTOR AGONIST EFFICACIOUS IN RODENT AND PRIMATE MODELS OF PARKINSONS-DISEASE
    ASIN, KE
    NIKKEL, A
    BEDNARZ, L
    DOMINO, EF
    SHIOSAKI, K
    FASEB JOURNAL, 1995, 9 (03): : A395 - A395
  • [4] BEHAVIORAL-EFFECTS OF CHRONIC EXPOSURE TO SELECTIVE D-1 AND D-2 DOPAMINE RECEPTOR AGONISTS
    BRAUN, AR
    CHASE, TN
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 147 (03) : 441 - 451
  • [5] BEHAVIORAL-EFFECTS OF FULL AND PARTIAL BENZAZEPINE-D(1) DOPAMINE AGONISTS IN THE MPTP-TREATED MARMOSET
    GNANALINGHAM, KK
    HUNTER, AJ
    JENNER, P
    MARSDEN, CD
    BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 : P49 - P49
  • [6] BEHAVIORAL-EFFECTS OF DOPAMINE D-1 AND D-2 RECEPTOR AGONISTS IN MONKEYS PREVIOUSLY TREATED WITH HALOPERIDOL
    LUBLIN, H
    GERLACH, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 153 (2-3) : 239 - 245
  • [7] A-86929 - A POTENT AND SELECTIVE DOPAMINE (DA) D1 AGONIST WITH EFFICACY IN RODENT AND PRIMATE MODELS OF PARKINSONS-DISEASE (PD)
    MICHAELIDES, MR
    ASIN, KE
    BIANCHI, B
    BRITTON, DR
    DIDOMENICO, S
    HODGES, L
    HONG, YF
    LIN, CW
    MIKUSA, J
    MILLER, T
    NIKKEL, A
    SMITH, L
    STASHKO, M
    WILLIAMS, M
    JENNER, P
    SHIOSAKI, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 83 - MEDI
  • [8] BEHAVIORAL-EFFECTS OF QUINPIROLE COMBINED WITH FULL AND PARTIAL EFFICACY D(1) DOPAMINE AGONISTS IN THE MPTP-TREATED MARMOSET
    GNANALINGHAM, KK
    HUNTER, AJ
    JENNER, P
    MARSDEN, CD
    BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 : P50 - P50
  • [9] THE INFLUENCE OF REPEATED TREATMENT WITH IMIPRAMINE, (+)-OXAPROTILINE AND (-)-OXAPROTILINE ON BEHAVIORAL-EFFECTS OF DOPAMINE D-1 AND D-2 AGONISTS
    MAJ, J
    PAPP, M
    SKUZA, G
    BIGAJSKA, K
    ZAZULA, M
    JOURNAL OF NEURAL TRANSMISSION, 1989, 76 (01) : 29 - 38
  • [10] DOPAMINE AGONISTS USED IN THE TREATMENT OF PARKINSONS-DISEASE AND THEIR SELECTIVITY FOR THE D-1 D-2, AND D-3 DOPAMINE-RECEPTORS IN HUMAN STRIATUM
    DEKEYSER, J
    DEBACKER, JP
    WILCZAK, N
    HERROELEN, L
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1995, 19 (07): : 1147 - 1154